---
schema_version: "secwatch.filing_event.v1"
accession: "0001599298-23-000088"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2023-10-16T23:59:59+00:00"
generated_at: "2026-06-09T23:19:49.117564+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Summit appoints Manmeet Soni as COO; Soni invests $5M, receives 28M options

## Summary
- Soni named COO effective Oct 13, 2023; invested $5M for 2.98M shares at $1.68/share.
- Soni compensation: $600K base, 60% bonus target, 28M options (14M time-vest, 14M performance-vest tied to mkt cap/revenue).
- Dr. Zanganeh granted 23.98M options with same time & performance vesting structure.
- Stockholders approved increase of shares under 2020 Stock Incentive Plan by 70M shares.
- Dave Gancarz, Urte Gayko, Fong Clow, Allen Yang promoted to C-suite roles.

## SEC filing metadata
- accession: 0001599298-23-000088
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2023-10-16T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 5.02, 3.02, 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000159929823000088/0001599298-23-000088-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000159929823000088/smmt-20231012.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001599298-23-000088
- JSON: https://secwatch.observer/filing/0001599298-23-000088.json
- Plain text: https://secwatch.observer/filing/0001599298-23-000088.txt

## Key facts
- Executive change
  Manmeet S. Soni was appointed as Chief Operating Officer at Summit Therapeutics Inc..
  - Action: appointed
  - Role: Chief Operating Officer
  source text: On October 13, 2023, the Company appointed Manmeet S. Soni as its Chief Operating Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1599298/000159929823000088/0001599298-23-000088-index.htm
- Material Agreements
  Summit Therapeutics Inc. entered into Securities Purchase Agreement with Manmeet S. Soni valued at $5,000,000 (effective 2023-10-13).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Manmeet S. Soni
  - Value: $5,000,000
  - Effective: 2023-10-13
  source text: On October 13, 2023, Summit Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement with Manmeet S. Soni pursuant to which Mr. Soni is investing $5,000,000 in the Company in exchange for 2,976,190 shares (the “Shares”) of the Company’s common stock (“Common Stock”), at a purchase price of $1.68 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1599298/000159929823000088/0001599298-23-000088-index.htm
- Shareholder Votes
  Summit Therapeutics Inc. shareholders approved Approve an amendment to the Plan to increase the number of shares of the Company’s common stock issuable under the Plan by 70,000,000 shares at the 2023-10-12 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2023-10-12
  source text: The Company held a Special Meeting of Stockholders (the “Special Meeting”) on October 12, 2023. The stockholders of the Company of record as of the close of business on September 18, 2023 were asked to vote on an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan (the “Plan”) to increase the number of shares of the Company’s common stock issuable under the Plan by 70,000,000 shares (the “Proposal”). The Proposal was approved at the Special Meeting by the requisite vote of the Company’s stockholders in accordance with the recommendation of the Company’s Board of Directors. Set forth below is the number of votes cast for, against or withheld, as well as the number of abstentions and broker non-votes, as to the Proposal: Proposal For Against Abstain Broker To approve an amendment to the Plan to increase the number of shares of the Company’s common stock issuable under the Plan by 70,000,000 shares. 567,632,197 7,904,039 167,675 —
  evidence_url: https://www.sec.gov/Archives/edgar/data/1599298/000159929823000088/0001599298-23-000088-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.